PuREC

PuREC Co., Ltd.

Basic information

Location (HQ)

Shimane, JP

Other location(s)

Tokyo, JP

Spinout from

Shimane University Medical School

Website

CEO

Established in 

Shotai Kobayashi

2016

Business descriptions

PuREC is currently preparing the IND for hypophosphatasia (a rare bone-formation deficiency disease for new born babies) with our uniquely purified MSC (mesenchymal stem cell). Two other orthopedic disease are expected to file IND in a few years. We are confident that our specially purified MSC, called “REC”, can be applied also for other disease areas as well.
As our first-in-human trial is expected to start in 2021, we seek for license partners and investors to solidify furhter development; esipecially in Europe and U.S.

Business field

Shimane University Medical School

Keywords

MSC

stem cell therapy

hypophosphatasia

disc herination

TRL

6

Key literatures

Company values

Number of filed patents

4

Patent IDs

Total patent value (USD)

No data

Business stage

Series A stage

Types of requested collaborations

R&D Collaboration, Investment, license partner

Ideal exit model

IPO in Japan

Introduction

PuREC is a spinout from Shimane University with patented technologies to produce purified MSC, or mesenchymal stem cells. PuREC's REC is coming from Rapidly Expanding Cells enabling the synthesis of 10^12 ordered pure cells within 12 weeks without requiring complicated methodologies such as gene-modification.

Licensing opportunity

(focusing on EU and US market)



Hypophosphatasia

Disc herniation

Joint disease

New applications including immunology diseases

Investment opportunity

Target $10M by 2022



Target other disease target POC

Create global business development team



Global investors outside Japan are also welcome